Precision Biologics
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
Search
  • Home
  • Company
    • About Us
    • Contact Us
    • Board
    • Leadership
  • Clinical
    • Pipeline
    • Companion Diagnostics
    • Therapeutics
    • Clinical Trials
  • Science
    • Publications
      • Recent
      • Historical
    • Abstracts
    • Posters
    • Presentations
  • News and Events
  • Home
  • News and Events
  • News

News

05JunJune 5, 2022

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

Strattmont Group2022-06-03T11:11:01-04:00

Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...

Facebook Twitter LinkedIn
Read more...
07AprApril 7, 2022

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference

Strattmont Group2022-04-11T11:45:35-04:00

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...

Facebook Twitter LinkedIn
Read more...
22MarMarch 22, 2022

Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”

Strattmont Group2022-04-11T11:43:49-04:00

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....

Facebook Twitter LinkedIn
Read more...
09MarMarch 9, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

Strattmont Group2022-03-09T10:48:47-05:00

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...

Facebook Twitter LinkedIn
Read more...
28JanJanuary 28, 2022

Precision Biologics, Inc. appoints Dr. Joyson Karakunnel to the Board of Directors

Strattmont Group2022-01-28T10:26:20-05:00

Dr. Joyson Karakunnel joins the Board of Directors of Precision Biologics, Inc. as its newest...

Facebook Twitter LinkedIn
Read more...
08NovNovember 8, 2021

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, November 8, 2021, Manchester, UK

Strattmont Group2021-11-05T14:50:15-04:00

Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...

Facebook Twitter LinkedIn
Read more...
29OctOctober 29, 2021

Phase II Clinical Trial NEO-201 in Combination with Pembrolizumab Detailed Study Information

Strattmont Group2021-10-28T11:57:03-04:00

The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...

Facebook Twitter LinkedIn
Read more...
28OctOctober 28, 2021

Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at 6th Annual Neoantigen Based Therapies Summit, October 26-28th, Digital Event

Strattmont Group2021-10-28T15:47:15-04:00

Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...

Facebook Twitter LinkedIn
Read more...
14OctOctober 14, 2021

Precision Biologics Commences Phase 2 Clinical Trial using NEO-201 and Pembrolizumab as a 2nd line Therapy in Patients with Solid Tumors

Strattmont Group2021-10-14T11:22:55-04:00

Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...

Facebook Twitter LinkedIn
Read more...
21AprApril 21, 2021

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen Summit 20th-22nd April 2021

Strattmont Group2021-04-21T08:30:59-04:00

Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...

Facebook Twitter LinkedIn
Read more...
12…4Next  

Featured News

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
June 5, 2022
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference
April 7, 2022
Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”
March 22, 2022
Want To Find Out More?

CONTACT INFO

301-500-8646

4814 Del Ray Avenue
Bethesda, MD 20814

COMPANY

Board
About Us
Contact Us
News and Events

CLINICAL

Pipeline
Diagnostics
Therapeutics
Clinical Trials

SCIENCE

Recent Publications
Publications – Historical
Abstracts
Posters
Presentations

© Copyright 2019-2021. Precision Biologics. All Rights Reserved.
Website Development By Strattmont Group